KerryAnneRogersMD

PubMed

• The evolving frontline management of CLL: are triplets better than doublets? How will we find out?
  Kerry A Rogers, Jennifer A Woyach
  Hematology. American Society of Hematology. Education Program. 2024-12-06
• Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia.
  Nilesh Kapoor, Qiuhong Zhao, Andrew Stiff, Seema A Bhat, Mirela I Anghelina
  Ejhaem. 2024-10-01
• 1 citations
  Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation.
  John Alan Gambril, Sanam M Ghazi, Stephen Sansoterra, Mussammat Ferdousi, Onaopepo Kola-Kehinde
  Leukemia. 2024-10-01

Abstracts/Posters

• Restoring Functional Deficits in Older Adults with Hematologic Malignancy
  Kerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia
  Kerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity
  Kerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study
  Kerry A Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
  Kerry A. Rogers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicent... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). 
  2019 ASCO Annual Meeting - 6/1/2019
• Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Change in tumor lysis syndrome risk after lead-in treatment in a phase 1b/2 study of obinutuzumab, ibrutinib, and venetoclax for chronic lymphocytic leukemia. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all